Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $50.36 in the last session, up 3.90% from day before closing price of $48.47. In other words, the price has increased by $3.90 from its previous closing price. On the day, 4.78 million shares were traded. RNA stock price reached its highest trading level at $51.39 during the session, while it also had its lowest trading level at $48.366.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50. On June 17, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.Wolfe Research initiated its Outperform rating on June 17, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 05 ’25 when Boyce Sarah sold 50,000 shares for $49.95 per share. The transaction valued at 2,497,435 led to the insider holds 305,871 shares of the business.
Mosbrooker Eric sold 6,563 shares of RNA for $308,936 on Sep 03 ’25. The Chief Commercial Officer now owns 55,000 shares after completing the transaction at $47.07 per share. On Sep 05 ’25, another insider, SARAH BOYCE, who serves as the Director of the company, bought 50,000 shares for $48.47 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 6478965248 and an Enterprise Value of 5300973056. For the stock, the TTM Price-to-Sale (P/S) ratio is 603.82 while its Price-to-Book (P/B) ratio in mrq is 5.10. Its current Enterprise Value per Revenue stands at 494.079 whereas that against EBITDA is -10.219.
Stock Price History:
The Beta on a monthly basis for RNA is 0.99, which has changed by 0.23552501 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 29.44%, while the 200-Day Moving Average is calculated to be 49.97%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 2.56M shares per day over the past 3-months and 2599380 shares per day over the past 10 days. A total of 120.78M shares are outstanding, with a floating share count of 115.96M. Insiders hold about 9.86% of the company’s shares, while institutions hold 103.18% stake in the company. Shares short for RNA as of 1755216000 were 15671917 with a Short Ratio of 6.12, compared to 1752537600 on 16259911. Therefore, it implies a Short% of Shares Outstanding of 15671917 and a Short% of Float of 12.29.
Earnings Estimates
A comprehensive evaluation of Avidity Biosciences Inc (RNA) is underway, with the input of 15.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.26, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.57. EPS for the following year is -$4.93, with 16.0 analysts recommending between -$2.97 and -$7.31.
